Giovanni Maconi © ECCO

Participating speakers and tutors: Anil Kumar Asthana (Australia), Arun Gupta (United Kingdom), Christian Maaser (Germany), Emma Calabrese (Italy), Francesca Maccioni (Italy) Jordi Rimola (Spain), Jaap Stoker (The Netherlands), Kerry Novak (Canada), Michael Torkzad (United Kingdom), Pietro Paolantonio (Italy), Rune Wilkens (Denmark), Torsten Kucharzik (Germany), Stephan Vavricka (Switzerland), Andrea Laghi (Italy) and Giovanni Maconi (Italy)

Giovanni Maconi © ECCO

Participating speakers and chairs: Simon Travis (United Kingdom), Raf Bisschops (Belgium), Raya Atreya (Germany), Peter Irving (United Kingdom), James Lindsay (United Kingdom), Matthieu Allez (France), Massimo Fantini (Italy) and Peter Lakatos (Hungary)

The ECCO Endoscopy Workshop reached its 3^rd edition in 2018 and has become a mainstay of the educational activities of ECCO. The workshop was organised by the Educational Committee (EduCom) and was designed to meet the needs of IBD specialists with some experience in endoscopy. 

Pascal Juillerat © ECCO

The 16^th Intensive Advanced IBD Course took place before the ECCO meeting as the highlight of the educational program which runs in conjunction with the conference.

This well-known course, which has been an a staple of the ECCO Congress almost since the beginning of ECCO, took place once again with a full attendance from Europe and abroad. Overall, 82 doctors attended the course from 37 countries and were treated to a comprehensive update on IBD.

Naila Arebi © ECCO

An introduction to pharmaco-epidemiology: How to interpret real world data for clinical practice 

The Epidemiological Committee (EpiCom) organised their 4^th workshop at the ECCO’18 Congress in Vienna.  Delegates were welcomed by Ebbe Langholz, who introduced the sessions with a short video on the UR-CARE database to illustrate the importance of databases and their potential across Europe. 

John Mansfield © ECCO

The 6^th ClinCom Workshop focussed on two current themes in IBD research: Evolving endpoints in clinical trials and comparative effectiveness research (CER).

Laurent Peyrin-Biroulet (Nancy, France) described the drivers that have led to the move from Crohn’s Disease Activity Index (CDAI) and Mayo scores to patient-reported outcomes (PROs) that just record clinical symptoms. The ultimate therapeutic goal is not only to reduce symptoms but also to return the patient to a normal life without disability. For Ulcerative Colitis (UC) the PRO uses rectal bleeding and stool frequency scores from the Mayo score, while for Crohn’s Disease (CD) abdominal pain and stool frequency scores are used. Many clinical trials also aim to show resolution of mucosal inflammation so endoscopic scores are frequently being used as co-primary endpoints with symptom scores. Some problems with PROs remain to be settled, especially the cut-off values for active disease, response and remission, and also the variability of patients’ assessment of loose stools and rectal bleeding.

Jihye Park © Jihye Park

Most patients with chronic IBD are diagnosed at a young age. After baseline diagnosis many of these young patients have to undergo repeated imaging procedures during the variable clinical course of their disease. Ultrasound, CT and MRI are used to image transmural alterations and extra-intestinal manifestations of the disease and to monitor response to treatment. 

Janneke van der Woude © ECCO

One of the main goals of ECCO is to promote IBD-related basic and clinical research as well as to foster interaction and productive collaboration among European research groups working in the IBD field. To achieve this goal, ECCO continues to award Grants, Fellowships and Travel Awards.

For 2018 the number of awardees has increased to an amazing total of more than 30.

Shomron Ben-Horin © ECCO

Michael Scharl © ECCO

Fat in IBD – Much more than an innocent bystander 

Within the framework of the 6^th SciCom Workshop, the role of fat and lipids in IBD pathogenesis was highlighted. Six highly interesting talks shed light on the fact that fat is much more than an innocent bystander in IBD.

Sandra Bohn Thomsen  © Sandra Bohn Thomsen

Evolution after anti-TNF discontinuation in patients with Inflammatory Bowel Disease: A multicentre long-term follow-up study

Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, et al.
Am J Gastroenterol. 2017;112:120–31

Kapil Sahnan  © Kapil Sahnan

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: A randomised controlled, open-label, multicentre trial 

Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, et al. 
Lancet Gastroenterol Hepatol. 2017;2:785–92.